Skip Navigation

Matthew Oser, MD, PhD


Make an Appointment

Physician

  • Instructor in Medicine at Dana-Farber Cancer Institute and Harvard Medical School

Clinical Interests

  • Thoracic oncology

Contact Information

  • Office Phone Number617-582-8668

Bio

Dr. Oser received his MD and PhD degrees from Albert Einstein College of Medicine in 2011. He received internal medicine training at Brigham and Women’s Hospital and his medical oncology fellowship training at Dana-Farber/Harvard Cancer Center. He is currently an Instructor in Medicine at Dana-Farber Cancer Institute and Harvard Medical School where he runs a research laboratory focused on small cell lung cancer and is a medical oncologist.

Board Certification:

  • Internal Medicine, 2014
  • Medical Oncology , 2016

Fellowship:

  • Dana-Farber/Harvard Cancer Center

Residency:

  • Brigham and Women's Hospital

Medical School:

  • Albert Einstein College of Medicine

Recent Awards:

  • Damon Runyon Clinical Investigator Award (2019)

Research

Identification of Novel Dependencies in Small Cell Lung Cancer (SCLC) that are a Consequence of Loss of Function Mutations in Tumor Suppressor Genes or from SCLCs Neuroendocrine Differentiation State
Although small cell lung cancer (SCLC) is initially highly responsive to chemotherapy, the disease recurs in nearly all patients in less than a year. At recurrence, there are no approved targeted therapies. Genomic sequencing of human SCLCs has shown that SCLCs have no actionable mutations and that nearly all SCLCs harbor loss of function (LOF) mutations in the tumor suppressor genes RB1 and TP53, while ~25% of SCLCs harbor LOF mutations in NOTCH.  Furthermore, sustained expression of neural/neuroendocrine lineage transcription factors ASCL1 and NEUROD1 are required for SCLC survival. However, ASCL1 and NEUROD1 are transcriptions factors and therefore are not directly druggable.
The Oser laboratory utilizes CRISPR-Cas9 screening approaches to identify new SCLC therapeutic targets that are either required for sustained expression of the neural/neuroendocrine lineage transcription factors ASCL1 and NEUROD1, or that are required for SCLC survival as a consequence of LOF mutations in tumor suppressor genes (i.e. are synthetic lethal interactors with SCLC tumor suppressor genes). In addition, we utilize a novel genetically-engineered mouse model of SCLC developed using CRISPR-Cas9 to study the consequences of inactivating novel candidate therapeutic targets during SCLC tumorigenesis. Ultimately, the Oser laboratory seeks to discover new targeted therapies for SCLC patients that function as synthetic lethal interactors with SCLC tumor suppressor genes or that function to block neuroendocrine differentiation.

Location

Dana-Farber Cancer Institute, Longwood Center (LC4202)
360 Longwood Ave
Boston, MA 02215
Get Directions

Top